Polyvinylpyrrolidone (PVP) mitigates the damaging effects of intracellular ice formation in adult stem cells.
Guha A., Devireddy R.
Laboratory Study, published in Ann Biomed Eng (2010) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Laboratory Study
- Journal
- Ann Biomed Eng (2010)
- Country
- United States
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 20177781
- DOI
- 10.1007/s10439-010-9963-z
Abstract (original English)
The objective of this work was to assess the effect of 10% (w/v) polyvinylpyrrolidone (PVP) on the pattern of intracellular ice formation (IIF) in human adipose tissue derived adult stem cells (ASCs) in the absence of serum and other cryoprotective agents (CPAs). The freezing experiments were carried out using a fluorescence microscope equipped with a Linkam cooling stage using two cooling protocols. Both the cooling protocols had a common cooling ramp: cells were cooled from 20 degrees C to -8 degrees C at 20 degrees C/min and then further cooled to -13 degrees C at 1 degrees C/min. At this point we employed either cooling protocol 1: the cells were cooled from -13 degrees C to -40 degrees C at a pre-determined cooling rate of 1, 5, 10, 20, or 40 degrees C/min and then thawed back to 20 degrees C at 20 degrees C/min; or cooling protocol 2: the cells were re-warmed from -13 degrees C to -5 degrees C at 20 degrees C/min and then re-cooled at a pre-determined rate of 1, 5, 10, 20, or 40 degrees C/min to -40 degrees C. Almost all (>95%) of the ASCs frozen in 1x PBS and protocol 1 exhibited IIF. However, almost none (<5%) of the ASCs frozen in 1x PBS and protocol 2 exhibited IIF. Similarly, almost all (>95%) of the ASCs frozen in 10% PVP in PBS and protocol 1 exhibited IIF. However, ~0, ~40, ~47, ~67, and ~100% of the ASCs exhibited IIF when frozen in 10% PVP in PBS and utilizing p
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.